BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting

BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined with PD-1 blockade LUND, SE / ACCESS Newswire / April 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that additional clinical data from its ongoing Phase 2a study evaluating BI-1808 in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in advanced ovarian cancer has been selected for a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago May 29 - June 2, 2026.